Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching to TAF-based STR (Genvoya) in Virologically Suppressed HIV-1
NCT01815736Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Mar 2013
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Started Mar 2013; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT01815736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01815736.